Hing C. Wong - 29 Jul 2026 Form 4 Insider Report for HCW Biologics Inc. (HCWB)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: HCWB
Reported as of: 29 Jul 2026
Net transaction value: +$59,998
SEC form: 4
Accepted by SEC: 31 Jul 2026, 16:10:11 UTC
Prior SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Nicole Valdivieso, as Attorney-in-Fact for Hing C. Wong

Key filing fact

Hing C. Wong filed Form 4 for HCW Biologics Inc. (HCWB) on 31 Jul 2026.

Key facts

This page summarizes Hing C. Wong's Form 4 filing for HCW Biologics Inc. (HCWB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Jul 2026, 16:10.

Change

Previous filing in this sequence was filed on 27 May 2026.
Current net transaction value: +$59,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001866258 Primary reporting owner

Wong Hing C

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O HCW BIOLOGICS, INC., 2929 N. COMMERCE PARKWAY, MIRAMAR,
Signature: /s/ Nicole Valdivieso, as Attorney-in-Fact for Hing C. Wong
Signature date: 31 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HCWB transaction

Common Stock

Purchase

Transaction value: $59,998
Shares: +23,210
Change %: +23%
Price: $2.58
Shares after: 125,845
Date: 29 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.